{"filings":[{"id":834557,"accession_number":"0001193125-26-255555","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-06-03T20:30:18+00:00","items":["2.03","8.01"],"status":"ready","headline":"Danaher subsidiary issues CHF 2.38B senior notes across seven tranches with maturities 2031-2056","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued CHF 2.38B senior notes via private placement; seven series with rates 1.65% to 2.51%.","Series A-D: CHF 119.5M-372.66M, rates 1.65%-2.25%, maturities 2031-2038.","Series E-G: CHF 382M-648.01M, rates 2.38%-2.51%, maturities 2041-2056.","Proceeds to be used for general corporate purposes, including acquisitions and share repurchases.","Notes unsecured, guaranteed by Danaher; closing June 3, 2026, interest semi-annual."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97910,"accession_number":"0000313616-26-000127","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Danaher shareholders approve Omnibus Incentive Plan, increase share reserve by 20 million shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shareholders approved the Amended and Restated Omnibus Incentive Plan, increasing share reserve by 20 million shares and extending term to May 5, 2036.","Plan approval vote: 553,836,647 for, 41,437,418 against, 509,591 abstain, 36,129,645 broker non-votes.","All 11 director nominees elected, with Linda Filler receiving 484.6M for and 110.4M against, and A. Shane Sanders receiving 439.3M for and 155.8M against.","Advisory say-on-pay proposal approved: 553,754,519 for, 41,555,863 against, 473,274 abstain, 36,129,645 broker non-votes.","Ratification of Ernst & Young as auditor for FY2026 approved: 595,609,858 for, 35,828,479 against, 474,964 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97909,"accession_number":"0001193125-26-191608","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Danaher issues €3.0B in senior notes to partially fund Masimo acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €500M floating rate notes due 2028, €750M 3.250% notes due 2030, €750M 3.625% notes due 2034, €1B 4.000% notes due 2038.","Net proceeds of ~€2.98B; intended to pay a portion of cash consideration for Masimo acquisition.","Special mandatory redemption at 101% if Masimo acquisition not consummated by Nov 16, 2026 or Merger Agreement terminated.","Notes are senior unsecured obligations, rank equally with existing and future unsecured senior debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97908,"accession_number":"0000313616-26-000109","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q1 adj EPS $2.06 (+9.5%), revenue $6.0B (+3.5%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $1.0B, diluted EPS $1.45; adjusted EPS $2.06, up 9.5% YoY.","Revenue $6.0B (+3.5% reported, +0.5% core); operating cash flow $1.3B, free cash flow $1.1B.","Full-year 2026 adjusted EPS guidance raised to $8.35-$8.55 from $8.35-$8.50; core revenue reaffirmed 3%-6%.","Announces intent to acquire Masimo Corporation, a patient monitoring solutions firm; no deal terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":5951000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97907,"accession_number":"0001193125-26-160383","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Danaher enters $5.0B 364-day revolving credit facility with Bank of America","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$5.0B 364-day revolving credit facility; expires April 15, 2027, with option to convert to term loans (+0.50% fee).","Loans priced at Term SOFR + 58.5-108.5 bps or Base Rate + 0-8.5 bps, based on debt rating.","Facility fee of 4.0 bps per annum on total commitments regardless of usage.","Financial covenant: Consolidated Leverage Ratio must not exceed 0.65 to 1.00.","Facility to support U.S. commercial paper program and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113105,"accession_number":"0001193125-26-053124","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","5.02","9.01"],"status":"ready","headline":"Danaher to acquire Masimo for $180/share cash, ~$9.9B enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash deal at $180/share; total enterprise value ~$9.9B including assumed debt.","Represents ~18x estimated 2027 EBITDA, or 15x including full annual synergies.","Masimo to operate as standalone company within Danaher's Diagnostics segment.","Expected to close H2 2026; subject to Masimo shareholder and regulatory approvals.","Expects $125M annual cost synergies and >$50M revenue synergies by year 5; EPS accretive $0.15–0.20 first year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113104,"accession_number":"0000313616-26-000058","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board Director Jessica L. Mega retires from Danaher Board effective Feb 5, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jessica L. Mega retired from Danaher's Board on Feb 5, 2026, due to other professional commitments.","No disagreement with Danaher's operations, policies, or practices was cited.","No replacement director was announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113103,"accession_number":"0000313616-26-000004","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q4 adj EPS $2.23 (+4%); revenue $6.8B (+4.5%); FY26 guidance $8.35-$8.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 adj EPS $2.23 (+4.0%); revenue $6.8B (+4.5%); non-GAAP core revenue +2.5%.","Full year 2025 adj EPS $7.80 (+4.5%); revenue $24.6B (+3.0%); core revenue +2.0%.","FY 2026 adj EPS guidance $8.35-$8.50; core revenue growth 3-6%; Q1 core low-single-digit growth.","Q4 operating cash flow $2.1B; free cash flow $1.8B. FY operating cash flow $6.4B; free cash flow $5.3B.","CEO says strong finish, exceeded Q4 expectations; expects continued gradual market improvement into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":24568000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113102,"accession_number":"0000313616-26-000002","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher estimates Q4 revenue up mid-single digits YoY; core revenue and FY EPS at high-end of guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated Q4 2025 revenue up mid-single-digit percent YoY; non-GAAP core revenue growth toward high-end of low-single-digit guidance.","Full-year 2025 adjusted diluted EPS expected toward high-end of $7.70–$7.80 guidance range.","CEO cites continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.","Danaher will report full Q4 and FY2025 earnings on January 28, 2026.","Presentation at J.P. Morgan Healthcare Conference on January 13; live webcast on Danaher's website."],"consensus_eps_estimate":null,"consensus_eps_actual":5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":24568000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129508,"accession_number":"0000313616-25-000198","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director John T. Schwieters to retire from Danaher board at 2026 annual meeting; board to reduce to 12 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John T. Schwieters has decided not to stand for reelection at Danaher's 2026 annual meeting and will retire from the Board effective as of that meeting.","His decision is not related to any disagreement with the Company on operations, policies, or practices.","The Board size will be reduced from 13 to 12 members upon his retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129507,"accession_number":"0000313616-25-000180","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q3 2025: EPS $1.27 GAAP, $1.89 adjusted; revenue up 4.5% to $6.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $908M ($1.27 diluted EPS); non-GAAP adjusted diluted EPS $1.89.","Revenue $6.1B, up 4.5% YoY; non-GAAP core revenue up 3.0% YoY.","Operating cash flow $1.7B; non-GAAP free cash flow $1.4B.","Full-year 2025 adjusted diluted EPS guidance maintained at $7.70-$7.80; core revenue expected low-single-digit growth.","Cepheid respiratory revenue better-than-anticipated; bioprocessing momentum cited as key driver."],"consensus_eps_estimate":null,"consensus_eps_actual":3.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":17730000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146067,"accession_number":"0000313616-25-000178","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Danaher authorizes new share repurchase program of up to 35 million shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repurchase of up to 35 million shares of common stock, with no expiration date.","Repurchases may be made on open market, privately, or via Rule 10b5-1 plans at management's discretion.","Program is in addition to prior authorizations; no impact on existing programs.","Bylaws amended with routine updates and enhanced advance notice requirements for shareholder proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146066,"accession_number":"0000313616-25-000172","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Danaher GC Brian Ellis to step down as General Counsel on Aug 25, 2025; retire Feb 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian W. Ellis, SVP and General Counsel, notified Danaher of plan to relinquish GC role effective August 25, 2025.","Ellis will continue as Senior Vice President until his retirement from the Company on February 28, 2026.","No replacement for General Counsel has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146065,"accession_number":"0000313616-25-000155","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Danaher names Matthew Gugino as CFO effective Feb 28, 2026; McGrew to remain EVP","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew M. McGrew to step down as CFO effective Feb 28, 2026, continue as Executive Vice President.","Matthew E. Gugino, currently Group CFO of Life Sciences Innovations, appointed CFO effective Feb 28, 2026.","Gugino's base salary increases to $700k now, $825k upon CFO start; equity target $4.2M in 2026.","McGrew's 2026 compensation: base salary $700k, target bonus 125%, equity $2.5M.","Gugino joined Danaher in 2013; previously at Barclays, Morgan Stanley, KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146064,"accession_number":"0000313616-25-000152","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q2 net earnings $555M, adjusted EPS $1.80; raises full-year adjusted EPS guidance to $7.70-$7.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $555M ($0.77 GAAP diluted EPS); adjusted diluted EPS $1.80.","Revenue $5.9B, +3.5% YoY; core revenue +1.5% YoY.","Operating cash flow $1.3B; free cash flow $1.1B.","Full-year 2025 adjusted EPS guidance raised to $7.70-$7.80 from $7.60-$7.75.","Q3 core revenue expected low-single digits growth; full-year core ~3% (unchanged)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11677000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164377,"accession_number":"0000313616-25-000110","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Danaher holds 2025 annual meeting; all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected 13 directors, each receiving majority FOR votes; lowest support was John T. Schwieters with ~420M FOR.","Ratified Ernst & Young as auditor for FY 2025: 599M FOR, 31M AGAINST, 1M abstain.","Advisory vote on executive compensation approved: 563M FOR, 31M AGAINST, 2.9M abstain, 34M broker non-votes.","Meeting held May 6, 2025; all proposals passed as recommended by the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164376,"accession_number":"0000313616-25-000090","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q1 adj. EPS $1.88 beats; revenues $5.7B; FY adj. EPS guidance $7.60-$7.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $1.0B ($1.32 GAAP EPS); adjusted diluted EPS $1.88, exceeding expectations.","Revenues decreased 1.0% to $5.7B; core revenue flat YoY.","Operating cash flow $1.3B; free cash flow $1.1B.","Q2 core revenue guided low-single digits growth; FY core revenue ~3% growth reaffirmed.","FY 2025 adjusted diluted EPS guidance initiated at $7.60-$7.75."],"consensus_eps_estimate":null,"consensus_eps_actual":1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":5741000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182137,"accession_number":"0000313616-25-000044","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Danaher appoints Charles W. Lamanna to Board effective Feb 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles W. Lamanna appointed to Danaher's Board, term expires at 2025 annual meeting; also appointed to Science & Technology Committee.","Lamanna will receive standard non-employee director compensation, including annual equity award, and has entered into indemnification agreement.","Board amended 2007 Omnibus Incentive Plan: upon death/disability, unvested stock options and RSUs fully vest; PSUs pay target shares.","Lamanna deemed independent under NYSE listing standards; no arrangements or transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182136,"accession_number":"0000313616-25-000004","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q4 net earnings $1.1B; guides FY2025 core revenue +3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 EPS $1.49 GAAP, $2.14 adjusted; revenue $6.5B (+2.0% YoY).","Full year 2024 revenue $23.9B flat; core revenue -1.5%; EPS $5.29 GAAP, $7.48 adjusted.","Q1 2025 core revenue expected to decline low-single digits; FY2025 core revenue +~3%.","Operating cash flow Q4 $2.0B, free cash flow $1.5B; full year $6.7B and $5.3B."],"consensus_eps_estimate":null,"consensus_eps_actual":5.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":23875000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182135,"accession_number":"0000313616-25-000002","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q4 2024 estimated revs up low-single digit; core revenue flat, beating guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated Q4 2024 revenues increase low-single digit percent year-over-year.","Non-GAAP core revenue essentially flat YoY, above prior guidance of low-single digit decline.","Full Q4 and FY 2024 earnings call set for Jan 29, 2025 at 8:00 a.m. ET.","CEO Rainer M. Blair to present at J.P. Morgan Healthcare Conference on Jan 14."],"consensus_eps_estimate":null,"consensus_eps_actual":5.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":23875000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198783,"accession_number":"0000313616-24-000251","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Pardis C. Sabeti retires from Danaher Board on Dec 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pardis C. Sabeti notified Danaher Board of her retirement effective December 10, 2024, citing time commitments.","Retirement not due to any disagreement with Danaher on operations, policies, or practices.","No replacement director announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198782,"accession_number":"0000313616-24-000223","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q3 adj EPS $1.71 beats; revenue $5.8B +3%; guides core rev down low-single digits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $818M ($1.12 GAAP EPS); adjusted diluted EPS $1.71, above expectations.","Revenue $5.8B, up 3.0% YoY; non-GAAP core revenue grew 0.5%.","Operating cash flow $1.5B, free cash flow $1.2B.","Q4 2024 core revenue expected to decline low-single digits YoY; full year 2024 still down low-single digits.","CEO cites stronger bioprocessing momentum and Cepheid market share gain."],"consensus_eps_estimate":null,"consensus_eps_actual":3.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":17337000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214814,"accession_number":"0000313616-24-000188","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q2 revenue down 3% to $5.7B, adjusted EPS $1.72 beats expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $907M, GAAP diluted EPS $1.22; non-GAAP adjusted EPS $1.72.","Revenue $5.7B, down 3.0% YoY; non-GAAP core revenue down 3.5%.","Operating cash flow $1.4B, free cash flow $1.1B.","CEO cites sustained momentum in bioprocessing and Cepheid market share gains.","Q3 and FY 2024 core revenue guided down low-single digits YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":11539000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233970,"accession_number":"0000313616-24-000174","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Danaher EVP Joakim Weidemanis to step down July 1, 2024; transition through Sept 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joakim Weidemanis resigns as Executive Vice President effective July 1, 2024; will remain employed through Sept 30, 2024 for transition.","Transition agreement provides continued base salary at $1,033,690 annual rate, pro-rated 2024 cash incentive with personal performance factor 1.0.","If terminated without cause during transition, he receives full salary and pro-rated bonus for the transitional period.","He reaffirms prior restrictive covenants and signs a general release of claims against Danaher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233969,"accession_number":"0000313616-24-000133","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Danaher shareholders elect all 13 directors; reject two shareholder proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; notable against votes: Teri List (28.6% against), John Schwieters (35.1%), A. Shane Sanders (26.5%).","Ratification of Ernst & Young as auditor passed with 94.4% votes for.","Advisory say-on-pay approved with 93.3% for.","Proposal to reduce special meeting threshold from 25% to 15% rejected (57% against).","Proposal requesting DEI effectiveness report rejected (86% against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233968,"accession_number":"0000313616-24-000106","cik":313616,"company_name":"DANAHER CORP /DE/","ticker":"DHR","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Danaher Q1 2024 beats expectations with $5.8B revenue, $1.92 adj EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $1.1B, diluted EPS $1.45; adjusted diluted EPS $1.92.","Revenue $5.8B, down 2.5% YoY; core revenue down 4.0%.","Operating cash flow $1.7B; free cash flow $1.4B.","CEO reports improving bioprocessing order trends and market share gains in molecular diagnostics at Cepheid.","Q2 core revenue expected down mid-single digits; full year 2024 core revenue expected down low-single digits."],"consensus_eps_estimate":null,"consensus_eps_actual":1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":5796000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":122536327420.3626,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}